Predicted coverage based on in vitro neutralizing activity of VRC01.
<p>Predicted coverage based on in vitro neutralizing activity of VRC01.</p
Medicine, Microbiology, Neuroscience, Pharmacology, Immunology, Cancer, Mental Health, Infectious Diseases, Virology, Computational Biology, Chemical Sciences not elsewhere classified, dose, peak serum VRC 01 levels, HVTN, findings HIV Vaccine Trials Network, 249 IV infusions, treatment group 1, treatment group 3, Serum VRC 01 levels, 208 SC injections, Trial registration Clinical Trials Registration, mg, Conclusions VRC 01, CD 4 binding site, VRC 01 concentrations, anti-VRC 01 antibodies, 8 weeks, CI, 2 weeks, VRC 01 administration regimen, 6 United States, SHIV, treatment group 2, simian-human immunodeficiency virus, placebo group 3, IC, IV infusion series, VRC 01, phase 1 randomized trial Background VRC 01, NCT, VRC 01 administration
DOI identifier: 10.1371/journal.pmed.1002435.t003
Sorry, we are unable to provide the full text but you may find it at the